The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Conditions:   Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency;   Autosomal Recessive Hypophosphatemic Rickets;   Generalized Arterial Calcification of Infancy Interventions:   Drug: INZ-701;   Drug: Control Arm (Conventional Therapy) Sponsor:   Inozyme Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials